Literature DB >> 2541665

Dietary supplementation with omega-3 fatty acids prolongs platelet survival in hyperlipidemic patients with atherosclerosis.

P H Levine1, M Fisher, P B Schneider, R H Whitten, B H Weiner, I S Ockene, B F Johnson, M H Johnson, E M Doyle, P A Riendeau.   

Abstract

Enhanced dietary omega-3 fatty acid consumption is thought to be associated with a reduced incidence of atherothrombotic disorders. This effect may be mediated in part through suppression of in vivo platelet activity by omega-3 fatty acids. We observed that platelet survival, a sensitive indicator of in vivo platelet activity was prolonged from 6.4 +/- 1.5 days to 7.7 +/- 1.4 days by moderate amounts of dietary omega-3 fatty acid supplementation for 6 weeks in a group of hyperlipidemic patients with preexisting, established atherothrombotic disorders. This effect on platelet survival was associated with a decrease in platelet arachidonic acid levels from 26.7 +/- 3.5% to 20.9% +/- 2.5% and a rise in platelet eicosapentaenoic and docosahexaenoic acid measurements from essentially undetectable to 2.8% +/- 1.6% and 1.9% +/- 1.0%. Plasma total cholesterol, low-density lipoprotein cholesterol, and serum apolipoprotein B levels rose significantly during the omega-3 fatty acid supplementation period. Platelet aggregation did not change. This study demonstrates that a modest amount of dietary omega-3 fatty acid supplementation can significantly effect in vivo platelet activity in a population at high risk for recurrent atherothrombotic disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541665

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  2 in total

Review 1.  New approaches to therapy with omega-3 fatty acids.

Authors:  Puneet Kakar; Timothy Watson; Gregory Y H Lip
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

2.  Propensity for young reticulated platelet recruitment into arterial thrombi.

Authors:  Robert D McBane; Catherine Gonzalez; David O Hodge; Waldemar E Wysokinski
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.